MedPath

In this study, the researchers want to understand how effective a drug called dexmedetomidine is in keeping the patients vital signs, such as blood pressure and heart rate, within a normal range during a medical procedure called modified electroconvulsive therapy (m-ECT).

Phase 2
Conditions
Health Condition 1: O- Medical and Surgical
Registration Number
CTRI/2024/05/067681
Lead Sponsor
Pt B D Sharma post graduate institute of medical sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

belonging to American Society of Anaesthesiologists (ASA) physical status of I-II, who are

diagnosed with mood disorder and undergoing modified ECT

Exclusion Criteria

Following patients will be excluded from study

1)Refusal to consent by relatives

2) History of underlying renal, hepatic, cardiac and pulmonary diseases

3)History of head trauma

4) Patients who do not have seizures after receiving m – ECT.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Effect on hemodynamic responses and post ictal agitationTimepoint: 15 min before ECT and upto 20 min after ECT
Secondary Outcome Measures
NameTimeMethod
1) Motor seizure duration (in seconds) <br/ ><br>2) Time to spontaneous breathing (in seconds) <br/ ><br>3) Responding time to verbal commands (in minutes)Timepoint: 1)SBP,SBP,MAP,HR,RPP at 1 min, 3 min,5 min,10 min and 20 min. <br/ ><br>2)Motor seizure duration <br/ ><br>3) Emergence agitation score at 30min <br/ ><br>
© Copyright 2025. All Rights Reserved by MedPath